Shionogi & Co., Ltd. - Unsponsored ADR (SGIOY)
OTC PINK OTC PINK Primary Summary
SGIOY Chart
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or Zoetis (ZTS).
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Masako Kudou - VP, Finance & Accounting Department Kazuhiro Hatanaka - Senior Executive Officer, Corporate Supervisory Unit & Corporate Strategy Division Toshinobu Iwasaki - SVP, Healthcare Business Unit Takeki Uehara - SVP, Drug Development & Regulatory Science Division Conference Call Participants Hidemaru Yamaguchi - Citi Eiji Ueda - Goldman Sachs Fumiyoshi Sakai - UBS Kazuaki Hashiguchi - Daiwa Securities Shinya Tsuzuki - Mizuho Securities Shinichiro Muraoka - Morgan Stanley Seiji Wakao - JPMorgan Yoshimasa Kyokawa This is Kyokawa of the Corporate Communication Department of Shionogi.
Shionogi & Co., Ltd. - Unsponsored ADR Dividends
| SGIOY 27 Mar 2024 | Other | $0.09 Per Share |
| SGIOY 28 Sep 2023 | Other | $0.08 Per Share |
| SGIOY 30 Mar 2023 | Other | $0.13 Per Share |
| SGIOY 29 Sep 2022 | Other | $0.07 Per Share |
| SGIOY 29 Mar 2022 | Other | $0.07 Per Share |
Shionogi & Co., Ltd. - Unsponsored ADR Earnings
| 28 Jul 2025 (In 3 days) Date | | 0.14 Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | 0.2 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 28 Oct 2024 Date | | - Cons. EPS | - EPS |
| SGIOY 27 Mar 2024 | Other | $0.09 Per Share |
| SGIOY 28 Sep 2023 | Other | $0.08 Per Share |
| SGIOY 30 Mar 2023 | Other | $0.13 Per Share |
| SGIOY 29 Sep 2022 | Other | $0.07 Per Share |
| SGIOY 29 Mar 2022 | Other | $0.07 Per Share |
| 28 Jul 2025 (In 3 days) Date | | 0.14 Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | 0.2 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 28 Oct 2024 Date | | - Cons. EPS | - EPS |
Shionogi & Co., Ltd. - Unsponsored ADR (SGIOY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Shionogi & Co., Ltd. - Unsponsored ADR ever had a stock split?
Shionogi & Co., Ltd. - Unsponsored ADR Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. Isao Teshirogi Ph.D. CEO | OTC PINK Exchange | 824667109 Cusip |
| JP Country | 4,955 Employees | 27 Mar 2024 Last Dividend | 27 Feb 2019 Last Split | - IPO Date |
Overview
Shionogi & Co., Ltd., founded in 1878 and headquartered in Osaka, Japan, originally operated as Shionogi Shoten Co., Ltd. before evolving its name in 1943. The company is deeply involved in the pharmaceutical industry, specializing in the research, development, manufacturing, and distribution of pharmaceuticals, diagnostic reagents, and medical devices primarily in Japan. Shionogi & Co., Ltd. is known for its significant contributions towards addressing complex health challenges, focusing on a range of treatments from infectious diseases to chronic conditions.
Products and Services
Fetroja: A treatment for multidrug-resistant gram-negative bacterial infections.
Cabenuva and Apretude: Includes anti-HIV drugs and prophylactics for HIV prevention.
Xocova: An oral treatment for COVID-19, contributing to the global effort against the pandemic.
Finibax: A carbapenem antibiotic designed for severe infections.
Xofluza: An antiviral drug targeting influenza, aiming to reduce the severity and duration of flu symptoms.
Tivicay: Another anti-HIV drug, part of Shionogi's effort to combat HIV/AIDS.
S-872600: An influenza nasal vaccine under development, representing Shionogi's innovative approach to vaccination.
S-875670: A COVID-19 nasal vaccine candidate, showcasing Shionogi's dedication to pandemic preparedness and response.
S-540956: A nucleic acid adjuvant, enhancing the effectiveness of vaccines.
Olorofim: Designed for the treatment of invasive aspergillosis, a serious fungal infection.
Cefiderocol: Targets aerobic gram-negative bacterial infections, addressing a critical need in infectious disease treatment.
Ensitrelvir: Aimed at treating and preventing COVID-19, highlighting Shionogi's ongoing commitment to pandemic response.
Baloxavir: An influenza virus infection treatment that further illustrates Shionogi's expertise in antiviral development.
BPN14770: Targeted for Alzheimer's disease and fragile X syndrome, addressing critical needs in neurological disorders.
Rizmoic: A solution for opioid-induced constipation, improving patient quality of life in pain management.
ADR-001: For decompensated liver cirrhosis, showcasing Shionogi’s innovation in treating serious liver conditions.
SDT-001: A treatment under development for inattentive ADHD, representing a focus on improving mental health and cognitive functions.
In addition to these, Shionogi & Co., Ltd. continues to explore a wide range of therapeutic areas, including treatments for solid tumors, chronic pain, obesity, bladder and esophageal cancer, acute ischemic stroke, depression, and type 2 diabetes. The expansive portfolio underscores Shionogi's commitment to advancing healthcare and improving the lives of patients worldwide.
Contact Information
